Experts review recent data & advances in drug development of anti-HER2 agents as they explore whether HER2-low is a unique #BreastCancer subtype: brnw.ch/21wI6qH #BCSM Maryam Lustberg MD MPH Adriana Kahn, MD David Rimm Yale Cancer Center @yalebreast #ASCODailyNews

Congratulations and welcome, everyone! 🇧🇷♥️🇺🇸

When your 1-year old’s toddler school lunch is much better than yours…!
I wish in public schools later this would also be a reality! For sure we would raise healthier food-conscious children. #food #children #publicschool

1/7 Multiple Antibody Drug Conjugates in #MBC = new options--can we use a different ADC after resistance to the first?

🚨 #TumorBoardTuesday case wrap up of Joannie M. Ivory, MD, MSPH, MHS & Yara Abdou, MD's excellent discussion!

Graphical summary 👇; read on to hear from the expert discussants!

RIP Edith Mitchell, M.D. May your family have peace and comfort after such an unexpected loss… Thank you for your legacy and for all the lives you touched 😞♥️

😂♥️😂 Yale Hematology Oncology Fellows YaleHematology Joshua Fein

1/💬 How does monarchE differ from other CDK4/6i trials? What is the significance/practical application of the subgroup analysis?

🎥 Aditya Bardia, MD will tell you all about it in the video below!
#SABCSUpdates
vimeo.com/895854180/9f91…

#bcsm

#bcsm

Don't miss the final #SABCSUpdates TONIGHT!

💬 Results from the phase 3 monarchE and NATALEE trials
👥 Aditya Bardia, MD, Adriana Kahn, MD, & Marija Sullivan
🕓 4:00 PM EST
📆 bit.ly/3t3Oifs

#MedEd #FOAMed #BreastCancer

3/ Is the benefit in monarchE or NATALEE sufficient to change your practice? #SABCSUpdates

ET ± abema (monarchE) or ribo (NATALEE) for HR+/HER2– EBC:
↑ IDFS, consistent in subgroups, but diminished benefit w/ MYC amplification
↑ DRFS or DDFS
OS trend ↑ but NS

4/📊 Which of the following AEs is associated w/ ribociclib, but not abemaciclib, treatment❓ #SABCSUpdates

5/ 📊 Which of the following genomic alterations was associated w/ a diminished IDFS benefit in patients receiving abema + ET in the phase 3 monarchE trial❓ #SABCSUpdates

6/ We hope you enjoyed this education on #breastcancer !

Complete the posttest & evaluation here 👉bit.ly/3tqnfv2
& claim your 🆓 CME!

In case you missed the previous #SABCSUpdates , check them out here:

bit.ly/TROPION
bit.ly/KEYNOTE756
bit.ly/CAPItello291

Deborah Augustus Integrity CE SoMe CME Maryam Lustberg MD MPH Adriana Kahn, MD Dionisia Quiroga, DO, PhD Margaret Gatti-Mays MD MPH FACP Hope Rugo Sarah Hurwitz Erika Hamilton, MD Promises to be a game-changer for patients with PD-L1+ tumors, particularly if ER-low (but not only). Need to see EFS data before changing practice. IO tox remains an issue, warranting extensive efforts in developing helpful biomarkers.

Survival data in upcoming years will be eagerly awaited!

This supports increasing number of TNBC trials including patients with ER/PR <10% instead of classically <1%, which biologically makes complete sense

Additional long term follow up with EFs needed as well as continued discussion on how these data fit into Post monarchE era - #bcsm Integrity CE SoMe CME

Continued recognition of ER low behaving biologically and prognostically similar to TNBC #bcsm Integrity CE SoMe CME